Preserving Beta-cell Function with Tocilizumab in New Onset Type 1 Diabetes


​This study is designed to test if the drug tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed with type 1 diabetes. There is evidence that giving medicines to affect the immune system, such as tocilizumab, may stop, delay, or decrease the destruction of beta cells, if given soon after diabetes is diagnosed. This may result in better glucose control.

​This study involves:

  • Tocilizumab or a placebo given via intravenous infusions monthly over a 6-month period.
  • Follow-up for an additional 18 months.
  • Periodic visits including blood draws and mixed meal tolerance tests.
  • Intensive diabetes management.


This study is no longer recruiting participants.


Principal Investigator: Dr. Jason Gaglia